Galectin Therapeutics (GALT) Preferred Stock Liabilities (2011 - 2026)

Galectin Therapeutics' Preferred Stock Liabilities history runs 16 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Preferred Stock Liabilities changed 0.0% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $1.7 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $1.7 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities held at $1.7 million in Q1 2026 per GALT's latest filing, from $1.7 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $1.7 million in Q1 2022 and bottomed at $1.7 million in Q1 2022.
• The 5-year median for Preferred Stock Liabilities is $1.7 million (2022), against an average of $1.7 million.
• Biggest YoY gain for Preferred Stock Liabilities was 0.0% in 2022; the steepest drop was 0.0% in 2022.
• Year by year, Preferred Stock Liabilities stood at $1.7 million in 2022, then changed by 0.0% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then changed by 0.0% to $1.7 million in 2025, then changed by 0.0% to $1.7 million in 2026.
• Per Business Quant, the three latest GALT Preferred Stock Liabilities figures stand at $1.7 million (Q1 2026), $1.7 million (Q4 2025), and $1.7 million (Q3 2025).